BUSINESS

• Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
  April 6, 2016

• JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
  April 6, 2016

• Astellas Strikes New Research Pact with AIST for Chagas’ Disease
  April 5, 2016

• GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
  April 4, 2016

• Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
  April 4, 2016

• Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
  April 4, 2016

• Astellas Completes Transfer of Dermatology Biz to LEO Pharma
  April 4, 2016

• Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
  April 4, 2016

• Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
  April 4, 2016

• Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
  April 4, 2016

• Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
  April 1, 2016

• Towa Prevails in Patent Suit over Elplat
  April 1, 2016

• Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
  April 1, 2016

• Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
  April 1, 2016

• Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
  April 1, 2016

• Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
  April 1, 2016

• Janssen Seeks MCL Indication for Imbruvica
  April 1, 2016

• HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
  March 31, 2016

• Eisai Transfers Thrombocytopenia Drug to US Investment Firm
  March 31, 2016

• Janssen Files Stelara for Crohn’s Disease
  March 31, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 464
• 465
• 466
• 467
• 468
• 469
• 470
• 471
• 472
• …
• Next ›
• 最終 »